Physician- and Patient-Reported Severity and Quality of Life Impact of Alopecia Areata: Results from a Real-World Survey in Five European Countries

被引:0
作者
Sergio Vañó-Galván
Ulrike Blume-Peytavi
Paul Farrant
Pascal Reygagne
Erin Johansson
Catherine Reed
Simran Marwaha
Frederick Durand
Bianca Maria Piraccini
机构
[1] University of Alcala,Ramón y Cajal University Hospital
[2] Charité-Universitätsmedizin,Department of Dermatology, Venerology and Allergology
[3] Brighton General Hospital,Department of Dermatology
[4] University Hospitals Sussex NHS Foundation Trust,Centre Sabouraud
[5] Hôpital Saint-Louis,Dermatology Unit
[6] Eli Lilly and Company,Department of Medical and Surgical Sciences
[7] Adelphi Real World,undefined
[8] IRCCS Azienda Ospedaliero-Universitaria Di Bologna,undefined
[9] University of Bologna,undefined
来源
Dermatology and Therapy | 2023年 / 13卷
关键词
Alopecia areata; Europe; Real-world; Burden; Patient-reported outcomes; Symptoms; Severity;
D O I
暂无
中图分类号
学科分类号
摘要
Alopecia areata (AA) can negatively affect quality of life and is associated with increased prevalence of anxiety and depression (vs people without AA). This study used surveys of adult patients with AA in Europe and their dermatologists to compare how doctors and patients assess AA severity. We also looked at how patients rate the overall burden and broader effects of AA (not just hair loss) according to whether their doctor classed their AA as ‘mild’, ‘moderate’ or ‘severe’. Data for 2083 patients were collected by 239 doctors; 561 patients completed questionnaires about their AA and its potential effects on their quality of life, mental health and ability to work or perform other activities. In 78.5% of cases (from 549 patients with both patient and doctor-rated severity), patients and their doctors agreed on the same AA severity category (mild, moderate or severe). However, in 15.7% of cases, doctors rated AA severity as being higher than reported by the patient, and in 5.8% of cases the patient classed their AA as being more severe than reported by the doctor. Data from patient questionnaires showed that the burden associated with AA was higher in patients with more severe AA (as per their doctor’s own definition of severity); anxiety/depression was the most commonly reported problem related to quality of life. This study highlights the significant impact that AA can have beyond hair loss, especially for patients with severe AA. Information from this study may help to inform appropriate treatment strategies for people with AA.
引用
收藏
页码:3121 / 3135
页数:14
相关论文
共 97 条
[1]  
Lintzeri DA(2022)Alopecia areata—current understanding and management J Dtsch Dermatol Ges 20 59-90
[2]  
Constantinou A(2023)The burden of alopecia areata: a scoping review focusing on quality of life, mental health and work productivity J Eur Acad Dermatol Venereol 187 73-81
[3]  
Hillmann K(2022)The associated burden of mental health conditions in alopecia areata: a population-based study in UK primary care Br J Dermatol 85 162-175
[4]  
Ghoreschi K(2021)Psychosocial and psychiatric comorbidities and health-related quality of life in alopecia areata: a systematic review J Am Acad Dermatol 166 916-926
[5]  
Vogt A(2012)British Association of Dermatologists' guidelines for the management of alopecia areata 2012 Br J Dermatol 12 825-834
[6]  
Blume-Peytavi U(2022)Defining severity in alopecia areata: current perspectives and a multidimensional framework Dermatol Ther (Heidelb) 26 213-218
[7]  
Muntyanu A(2012)Disease severity evaluation among dermatological out-patients: a comparison between the assessments of patients and physicians J Eur Acad Dermatol Venereol 66 e97-102
[8]  
Gabrielli S(2012)Clinical severity does not reliably predict quality of life in women with alopecia areata, telogen effluvium, or androgenic alopecia J Am Acad Dermatol 49 575-583
[9]  
Donovan J(2022)Patient and physician perspectives on alopecia areata: a real-world assessment of severity and burden in Japan J Dermatol 142 2646-2650
[10]  
Macbeth AE(2022)Predictors of QOL in patients with alopecia areata J Invest Dermatol 24 3063-3072